[go: up one dir, main page]

WO2024243189A3 - Antigen binding proteins targeting pd-1 - Google Patents

Antigen binding proteins targeting pd-1 Download PDF

Info

Publication number
WO2024243189A3
WO2024243189A3 PCT/US2024/030337 US2024030337W WO2024243189A3 WO 2024243189 A3 WO2024243189 A3 WO 2024243189A3 US 2024030337 W US2024030337 W US 2024030337W WO 2024243189 A3 WO2024243189 A3 WO 2024243189A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen binding
binding proteins
present disclosure
proteins targeting
mouse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/030337
Other languages
French (fr)
Other versions
WO2024243189A2 (en
Inventor
Michael A. Curran
Shweta Mahendra HEGDE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of WO2024243189A2 publication Critical patent/WO2024243189A2/en
Publication of WO2024243189A3 publication Critical patent/WO2024243189A3/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present disclosure provides antigen binding proteins that specifically bind PD-1. The present disclosure further provides mouse anti-mouse PD-1 blocking antibodies, engineered cells, and methods of making and using the antigen binding proteins, anti-PD-1 antibodies, and cells of the disclosure. Aspects of the disclosure further relate to a polypeptide comprising any one of the complementary determining regions of the present disclosure.
PCT/US2024/030337 2023-05-22 2024-05-21 Antigen binding proteins targeting pd-1 Pending WO2024243189A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363503632P 2023-05-22 2023-05-22
US63/503,632 2023-05-22

Publications (2)

Publication Number Publication Date
WO2024243189A2 WO2024243189A2 (en) 2024-11-28
WO2024243189A3 true WO2024243189A3 (en) 2025-04-17

Family

ID=93590428

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/030337 Pending WO2024243189A2 (en) 2023-05-22 2024-05-21 Antigen binding proteins targeting pd-1

Country Status (1)

Country Link
WO (1) WO2024243189A2 (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090068202A1 (en) * 2007-07-16 2009-03-12 Genentech, Inc. Humanized Anti-CD79B Antibodies and Immunoconjugates and Methods of Use
US20110171220A1 (en) * 2008-09-12 2011-07-14 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
US20110250630A1 (en) * 2002-04-09 2011-10-13 Burton Dennis R Motif-grafted hybrid polypeptides and uses thereof
US20200399389A1 (en) * 2018-03-09 2020-12-24 Phanes Therapeutics, Inc. Anti-cd73 antibodies and uses thereof
WO2021216537A1 (en) * 2020-04-20 2021-10-28 Ab Studio Inc. Anti-coronavirus antibodies and uses thereof
WO2022053701A1 (en) * 2020-09-14 2022-03-17 Universita' Degli Studi Di Torino Anti-morgana monoclonal antibody for the treatment of tumors
US20230139885A1 (en) * 2020-03-11 2023-05-04 Fundació Institut De Recerca Contra La Leucèmia Josep Carreras Cd22 targeting-moiety for the treatment of b-cell acute lymphoblastic leukemia (b-all)

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110250630A1 (en) * 2002-04-09 2011-10-13 Burton Dennis R Motif-grafted hybrid polypeptides and uses thereof
US20090068202A1 (en) * 2007-07-16 2009-03-12 Genentech, Inc. Humanized Anti-CD79B Antibodies and Immunoconjugates and Methods of Use
US20110171220A1 (en) * 2008-09-12 2011-07-14 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
US20200399389A1 (en) * 2018-03-09 2020-12-24 Phanes Therapeutics, Inc. Anti-cd73 antibodies and uses thereof
US20230139885A1 (en) * 2020-03-11 2023-05-04 Fundació Institut De Recerca Contra La Leucèmia Josep Carreras Cd22 targeting-moiety for the treatment of b-cell acute lymphoblastic leukemia (b-all)
WO2021216537A1 (en) * 2020-04-20 2021-10-28 Ab Studio Inc. Anti-coronavirus antibodies and uses thereof
WO2022053701A1 (en) * 2020-09-14 2022-03-17 Universita' Degli Studi Di Torino Anti-morgana monoclonal antibody for the treatment of tumors

Also Published As

Publication number Publication date
WO2024243189A2 (en) 2024-11-28

Similar Documents

Publication Publication Date Title
WO2005061547A3 (en) Bispecific antibodies
PH12021500051A1 (en) Cd3 antigen binding fragments and compositions comprising same
IL299221A (en) Cd3 binding antibodies
EA202191457A1 (en) ANTI-PD-L1 / ANTI-4-1BB BISPECIFIC ANTIBODIES AND THEIR APPLICATIONS
EP4286415A3 (en) Humanized antigen-binding domains against cd19 and methods of use
JP2020522254A5 (en)
IL265541B1 (en) Bispecific antibodies and compounds containing them for the treatment of cancer
WO2019160751A3 (en) Methods for treating cancer with anti-pd-1 antibodies
MX2022010665A (en) Antibodies binding il4r and uses thereof.
MY202157A (en) Anti-pd-l1 antibody and use thereof
PH12022552520A1 (en) Antibodies binding siglec15 and uses thereof
MX2023004275A (en) Anti-pd-1/cd40 bispecific antibodies and uses thereof.
ZA202308896B (en) Antibodies binding trop2 and uses thereof
MX2022003432A (en) Methods and compositions comprising an anti-ctla4 monoclonal antibody with reduced host cell proteins and increased polysorbate-80 stability.
WO2024243189A3 (en) Antigen binding proteins targeting pd-1
WO2021050857A8 (en) Anti-cd371 antibodies and uses thereof
AR120430A1 (en) CAR-T CELLS DIRECTED TO EPHA3 FOR THE TREATMENT OF TUMORS
WO2023202672A9 (en) Antibodies targeting sirp-alpha and uses thereof
WO2020257789A3 (en) Anti-tim-3 antibodies
MX2024009292A (en) Anti-her2/trop2 antibodies and uses thereof.
PH12023550019A1 (en) Antibodies which bind to cancer cells and target radionuclides to said cells
MX2021016066A (en) Heterodimeric antibodies that bind to cd38 and cd3.
WO2021118156A3 (en) Switching binder, preparation method therefor, and pharmaceutical composition, assay kit, and antigen and antibody assay method, each using same
WO2023196947A3 (en) Methods for activation and expansion of engineered natural killer cells and combinations with antibodies
MX2022009138A (en) Conditionally active anti-her2 antibodies, antibody fragments their immunoconjugates and uses thereof.